Anifrolumab ELISA Kit (DB823018)

Fiche technique Partager le produit Copier les informations

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	DB823018
Description	Anifrolumab ELISA Kit (DB823018) — Quantitative competitive ELISA for Anifrolumab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL. Sensitivity: 0.156 μg/ml. Highlights ●Competitive Format — High specificity, reliable quantification. ●High Sensitivity — Optimized for low-abundance target detection. ●Ready-to-Use — Complete kit with pre-coated plates included.
Type d'échantillon	Plasma, Serum
Sensibilité	69.49 ng/ml
Plage	93.75-6,000 ng/ml
Numéro d'accès	P17181
Applications	ELISA
Méthode de détection	Colorimetric
Type de test	Quantitative
Retraitement	80-120%
Expédition	2-8 ℃
Stabilité et stockage	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Spécifications	Anifrolumab
Noms alternatifs	MDX-1333, MEDI-546, 1326232-46-5
Contexte	Interferon alpha/beta receptor 1 (Anifrolumab) is a ~63 kDa protein. Together with IFNAR2, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa). Type I interferon binding activates the JAK-STAT signaling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response. Mechanistically, type I interferon-binding brings the IFNAR1 and IFNAR2 subunits into close proximity with one another, driving their associated Janus kinases (JAKs) (TYK2 bound to IFNAR1 and JAK1 bound to IFNAR2) to cross-phosphorylate one another. The activated kinases phosphorylate specific tyrosine residues on the intracellular domains of IFNAR1 and IFNAR2, forming docking sites for the STAT transcription factors. STAT proteins are then phosphorylated by the JAKs, promoting their translocation into the nucleus to regulate expression of interferon-regulated genes. 1. Russell-Harde, D. et al. (1999) Biochemical and biophysical research communications 255, 539-44. PMID: 10049744 2. Kumar, KG. et al. (2003) The EMBO journal 22, 5480-90. PMID: 14532120 3. Kumar, KG. et al. (2004) The Journal of biological chemistry 279, 46614-20. PMID: 15337770 4. Uzé, G. et al. (1990) Cell 60, 225-34. PMID: 2153461 5. Thomas, C. et al. (2011) Cell 146, 621-32. PMID: 21854986 6. Zheng, H. et al. (2013) Cell reports 5, 180-93. PMID: 24075985 7. Hernandez, N. et al. (2019) The Journal of experimental medicine 216, 2057-2070. PMID: 31270247 8. Gothe, F. et al. (2022) Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 74, 136-139. PMID: 33252644 9. Bastard, P. et al. (2022) The Journal of experimental medicine 219. PMID: 35442418 10. Abramovich, C. et al. (1994) The EMBO journal 13, 5871-7. PMID: 7813427
Note	For Research Use Only.